These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 18620939

  • 1. Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty.
    Mariani S, Giona F, Basciani S, Brama M, Gnessi L.
    Lancet; 2008 Jul 12; 372(9633):111-112. PubMed ID: 18620939
    [No Abstract] [Full Text] [Related]

  • 2. Bilateral masculine mastoplasia associated with imatinib mesylate: a case report and literature review.
    Zhao D, Wang G, Li C, Meng L.
    J Huazhong Univ Sci Technolog Med Sci; 2011 Feb 12; 31(1):145-146. PubMed ID: 21336741
    [No Abstract] [Full Text] [Related]

  • 3. Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty.
    Giona F, Mariani S, Gnessi L, Moleti ML, Rea M, De Vellis A, Marzella D, Testi AM, Foà R.
    Haematologica; 2013 Mar 12; 98(3):e25-7. PubMed ID: 22983586
    [No Abstract] [Full Text] [Related]

  • 4. Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate.
    Arora B, Kumar L, Sharma A, Wadhwa J, Kochupillai V.
    Ann Oncol; 2004 Feb 12; 15(2):358-9. PubMed ID: 14760137
    [No Abstract] [Full Text] [Related]

  • 5. Imatinib mesylate: a new pill for chronic myelogenous leukemia.
    Parmar KK, King RS.
    Cancer Pract; 2001 Feb 12; 9(5):263-5. PubMed ID: 11879324
    [No Abstract] [Full Text] [Related]

  • 6. Imatinib mesylate induced immune thrombocytopenia.
    Rajappa S, Varadpande L, Paul TR, Digumarti R.
    Leuk Lymphoma; 2007 Nov 12; 48(11):2261-3. PubMed ID: 17926182
    [No Abstract] [Full Text] [Related]

  • 7. Imatinib mesylate.
    Am J Health Syst Pharm; 2001 Dec 01; 58(23):2241-2. PubMed ID: 11765724
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Gleevec: tailoring to fit.
    May TS.
    Drug Discov Today; 2003 Mar 01; 8(5):188-9. PubMed ID: 12634004
    [No Abstract] [Full Text] [Related]

  • 13. Imatinib-induced nail hyperpigmentation in chronic myeloid leukemia.
    Prabhash K, Biswas G, Prasad N, Karant N, Sastry PS, Parikh PM.
    Indian J Dermatol Venereol Leprol; 2006 Mar 01; 72(1):63-4. PubMed ID: 16481719
    [No Abstract] [Full Text] [Related]

  • 14. [Imatinib mesylate-induced acute cytolytic hepatitis].
    Rocca P, El Jastimi S, Troncy J, Scoazec JY, Boucher A, Vial T, Trépo C, Zoulim F.
    Gastroenterol Clin Biol; 2004 Oct 01; 28(10 Pt 1):918-9. PubMed ID: 15523233
    [No Abstract] [Full Text] [Related]

  • 15. Leukemia. Q&A highlights.
    Frame D, Sessions J, Fausel C.
    Am J Health Syst Pharm; 2007 Dec 15; 64(24 Suppl 15):S22. PubMed ID: 18056929
    [No Abstract] [Full Text] [Related]

  • 16. Imatinib for chronic myeloid leukaemia: a NICE mess.
    Lim D, Muir J.
    Lancet; 2001 Dec 01; 358(9296):1903. PubMed ID: 11741656
    [No Abstract] [Full Text] [Related]

  • 17. A patient of chronic myelogenous leukemia developing painful rash on feet.
    Kumar P, Das NK, Sil A, Chakrabarti P.
    J Postgrad Med; 2012 Dec 01; 58(4):331-4. PubMed ID: 23298941
    [No Abstract] [Full Text] [Related]

  • 18. A case of chronic myeloid leukemia with eosinophilic interstitial pneumonitis after administration of imatinib mesylate for 11 months.
    Suemori K, Fujiwara H, Watanabe S, Azuma T, Yasukawa M.
    Int J Hematol; 2010 Dec 01; 92(5):777-8. PubMed ID: 21110146
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.